The presence of TP53 mutations in MDS del(5q) is associated with lower response rates to lenalidomide, which would be consistent with the fact that the patient did not achieve cytogenetic response even when hemoglobin levels improved after treatment. Here, TP53 is linked to myelodysplastic syndrome.